![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Week 48 pharmacokinetic and pharmacodynamic results of darunavir 800mg once daily when co-administered with cobicistat 150mg once daily in HIV-1-infected patients with no darunavir resistance-associated mutations: GS-US-216-0130
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, USA, May 19-21, 2014
Thomas N Kakuda,1 Anne Brochot,2 Joseph M Custodio,3 Bruce Green,4 Simon Vanveggel,5 Tom Van De Casteele,5 Magda Opsomer,5 Frank L Tomaka,1 Marshall W Fordyce,3 Richard MW Hoetelmans5
1Janssen Research & Development LLC, Titusville, NJ, USA; 2Janssen Research & Development, Beerse, Belgium; 3Gilead Sciences, Foster City, CA, USA; 4Model Answers Pty Ltd, Brisbane, Australia; 5Janssen Infectious Diseases BVBA, Beerse, Belgium
![Pharm1.gif](../images/061114/061114-2/Pharm1.gif)
![Pharm2.gif](../images/061114/061114-2/Pharm2.gif)
![Pharm3.gif](../images/061114/061114-2/Pharm3.gif)
![Pharm4.gif](../images/061114/061114-2/Pharm4.gif)
![Pharm5.gif](../images/061114/061114-2/Pharm5.gif)
![Pharm6.gif](../images/061114/061114-2/Pharm6.gif)
![Pharm7.gif](../images/061114/061114-2/Pharm7.gif)
![Pharm8.gif](../images/061114/061114-2/Pharm8.gif)
![Pharm9.gif](../images/061114/061114-2/Pharm9.gif)
![Pharm10.gif](../images/061114/061114-2/Pharm10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|